AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02757859 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lavage
Description: Receive EIPL-D
Study NCT02757859 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Pancreatectomy
Description: Undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy
Study NCT01401192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin
Description: Gemcitabine 1000mg/m2 D1, D8 \& cisplatin 70mg/m2 D1 every 3 weeks
Study NCT01401192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed plus cisplatin
Description: Pemetrexed 500mg/m2 \& cisplatin 70mg/m2 D1 every 3 weeks
Study NCT01401192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed plus cisplatin
Description: pemetrexed 500mg/m2 \& cisplatin 70mg/m2 every 3 weeks
Study NCT00116727 — intervention group
Intervention type: DRUG
Intervention: ENBREL®
Description: 50 mg/wk SC
Study NCT03113903 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychophysical exploration
Description: Psychophysical exploration (multimodal sensitivity, including pain sensitivity) Electronic von Frey applied on forearm; thermal heat applied on forearm; foot immersion in 2°C cold water; exposure to a one-frequency noise up to uncomfortable loudness ; exposure to a halogen-lamp-generated light up to uncomfortable brightness.
Study NCT03113903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychophysical exploration
Description: Psychophysical exploration (multimodal sensitivity, including pain sensitivity) Electronic von Frey applied on forearm; thermal heat applied on forearm; foot immersion in 2°C cold water; exposure to a one-frequency noise up to uncomfortable loudness ; exposure to a halogen-lamp-generated light up to uncomfortable brightness.
Study NCT06158685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Group
Description: Treatment: Hyperextension exercises as described by McKenzie (in addition to the conventional physiotherapy program)~McKenzie Hyperextension Exercises:~* Exercises:~  1. Prone position, arms by the side, deep breath, relax back muscles, holding for 2-3 minutes.~ 2. Prone position, raise trunk by raising head above forearms, elbows at shoulder level, maintaining for 2-3 minutes (10 repetitions).~ 3. Prone position, hands at elbow level, straighten elbows, raise the upper body from the floor and backwards as far as pain permits, holding for 2-3 seconds (10 repetitions).~ 4. Standing with feet shoulder-width apart, hands on waist, leaning backwards as far as possible from the lumbar region without bending knees, holding for 2-3 seconds (10 repetitions).~     Additional Information:~* Researcher Consistency: All treatments and evaluations were performed by the same researcher.~Frequency: 5 days a week Duration: 3 consecutive weeks
Study NCT06158685 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Treatment: Conventional physiotherapy program~* Components:~  * Hot pack was applied to the lumbar region for 20 minutes~ * Ultrasound (ITO device) at 1 MHz and 1.5 W/cm2 for 5 minutes~ * Transcutaneous Electrical Nerve Stimulation (TENS) at 50-100 Hz for 20 minutes~ * Researcher Consistency: All treatments and evaluations for both groups were performed by the same researcher.~* Session Duration: An average of 45 minutes per session~* Frequency: 5 days a week~* Duration: 3 consecutive weeks~* Total Sessions: 15
Study NCT04780347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound paclitaxel plus capecitabine
Description: Albumin-bound paclitaxel plus capecitabine: Albumin-bound paclitaxel 260mg/m2, IV , D1, q3w； capecitabine 1000 mg/m2, PO，bid, D1-14,q3w.
Study NCT04780347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: capecitabine: capecitabine 1000 mg/m2, PO，bid, D1-14,q3w.
Study NCT02294916 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AWS
Description: Video-laryngoscopy 1
Study NCT02294916 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubrite
Description: Video-laryngoscopy 2
Study NCT02294916 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AirTraq
Description: Optical-laryngoscopy
Study NCT02294916 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIL
Description: Direct-laryngoscopy
Study NCT01207037 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood samples and scintigraphy
Description: at 3 months, 6 months, 12 months, 18 months and 24 months will allow a clinical evaluation and an additional sampling of blood of 5 mL at each visit Scintigraphy at 6 months and 18 months
Study NCT00004145 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Study NCT00004145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00004145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Study NCT00004145 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT02939547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxypropyl-beta-cyclodextrin
Description: Used in the treatment of Niemann-Pick Disease C1 ( NPC1)
Study NCT02779478 — intervention group
Intervention type: PROCEDURE
Intervention: Bronchoscopy
Study NCT03634696 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mPCL
Description: Smart phone application to support palliative care among late-stage cancer patients
Study NCT03634696 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care through OCRI palliative care clinic
Study NCT04506268 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opt-out Recruitment Email
Description: Behaviorally informed, opt-out framed recruitment email
Study NCT04506268 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opt-in Recruitment Email
Description: Standard, opt-in framed recruitment email
Study NCT03172676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin 50 mg/kg/day in 2 divided doses for 14 days.
Description: chronic immune thrombocytopenic purpura patients who will be diagnosed positive for helicobacter pylori infection will receive Amoxicillin for 14 days.
Study NCT03172676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin 15 mg/kg/day in 2 divided doses for 14 days.
Description: chronic immune thrombocytopenic purpura patients who will be diagnosed positive for helicobacter pylori infection will receive Clarithromycin for 14 days.
Study NCT03172676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proton pump inhibitor 1 mg/kg/day in 2 divided doses 1 month
Description: chronic immune thrombocytopenic purpura patients who will be diagnosed positive for helicobacter pylori infection will receive proton pump inhibitor for 1 month.
Study NCT03556241 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Case management
Description: Case management consists keeping patient's current pacemaker mode during surgery
Study NCT01638494 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Colecalcium supplement
Description: Daily Ca2+ and VitD intake was determined using a previously validated written dietary questionnaire, filled by the parents with the help of a registered dietitian. Eventual assumption of Ca2+ and/or VitD supplements or fortified foods was also registered. All questionnaires were collected and analyzed using a specific software based on the Italian food composition tables (Winfood, Medimatica SRL, Martinsicuro, Teramo, Italy). All data were recorded in a specific clinical chart before statistical analysis. All subjects with less than 70% of the DRIs were invited to participate in a randomized trial aiming to investigate the efficacy of different nutritional interventions. The dietitian gave information to the parents on how to improve the consumption of foods rich in Ca2+ and VitD according to DRIs. No nutritional support products were prescribed in children enrolled in group 2.
Study NCT02951741 — intervention group
Intervention type: OTHER
Intervention: RTHRA group
Description: hematologic variables measurement in patients undergoing revision total hip replacement
Study NCT01145755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2066
Description: 18 mg once daily
Study NCT01145755 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01145755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: 60 mg once daily
Study NCT00547365 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human immune globulin intravenous (IGIV)
Description: Analyze the therapeutic potential of human immune globulin intravenous (IGIV) when given to patients with cardiac-associated AL amyloidosis
Study NCT01018121 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LAUNCH
Description: A 6-month intervention consisting of two phases: Phase I (Intensive Intervention), 12 weekly sessions that alternated between group-based clinic sessions (parent and child concurrent groups) and individual home visits and Phase II (Maintenance), 12 weeks of every other week sessions, alternating between group sessions in-clinic and home sessions. Targeted 3 components: 1) Dietary education with age-specific caloric targets, healthy eating recommendations for children following the AAP guidelines used in the PC session; 2) Physical Activity education with age-specific activities for children and families; and 3) Parenting skills to achieve the diet and physical activity goals using behavioral management skills and parent modeling of eating and activity.
Study NCT02833233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study NCT02833233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT01018121 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pediatrician Counseling
Description: A one time 45-minute visit with a board certified pediatrician for each family that focused on the AAP guidelines for eating and physical activity for children
Study NCT02181712 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell 0.5
Description: 0.5 million MSC per Kg will be infused intravenously. Product will be infused at the rate of 2 - 3 ml/minute during the first 15 minutes and may be adjusted up to 5ml/minutes if tolerable. It is anticipated that the infusion will be completed within approximately 3 hours.
Study NCT02181712 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell 1.0
Description: 1 million MSC per Kg will be infused intravenously. Product will be infused at the rate of 2 - 3 ml/minute during the first 15 minutes and may be adjusted up to 5ml/minutes if tolerable. It is anticipated that the infusion will be completed within approximately 3 hours.
Study NCT00351143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training
Description: Salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training will be provided to intervention group in Period 2.
Study NCT00351143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salmeterol/fluticasone propionate 50/250 µg
Description: Salmeterol/fluticasone propionate 50/250 µg will be administered to control group in Period 2
Study NCT00351143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salmeterol/fluticasone propionate 50/250 µg
Description: Salmeterol/fluticasone propionate 50/250 µg will be administered to control group in Period 2
Study NCT02686060 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 0.2 micron positively charged PALL Corporation filters and 1.2 micro IV in-line filters used for lipid administration
Study NCT02949258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: oxaliplatin 150 mg will be administered from the celiac artery on day 1 of every cycle in all cases
Study NCT02949258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: etoposide 100 mg will be administered from the celiac artery on day 1 of every cycle in all cases
Study NCT02352896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPI-743
Description: EPI-743 100 milligrams/milliliter (mg/mL) oral solution will be administered per dose and schedule specified in the arm.
Study NCT02949258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin
Description: epirubicin 30 mg will be administered from the celiac artery on day 1 of every cycle in all cases
Study NCT02949258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: Oral S-1 120 mg per day will be administered on days 1-14 of every cycle in all cases
Study NCT06415006 — intervention group
Intervention type: PROCEDURE
Intervention: Measurement of hemodynamic parameters.
Description: The measurement and recording of Heart Rate (HR), Systolic Arterial Blood Pressure (ABPsys), Diastolic Arterial Blood Pressure (ABPdias), Mean Arterial Blood Pressure (ABPmean), and age parameters.
Study NCT02265367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levomilnacipran
Study NCT02265367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02575820 — intervention group
Intervention type: PROCEDURE
Intervention: Old red blood cells transfusion
Description: Red blood cells (shelf life > 14 days) transfusion during the operation (total hip replacement arthroplasty)
Study NCT02575820 — intervention group
Intervention type: PROCEDURE
Intervention: New red blood cells transfusion
Description: Red blood cells (shelf life =\< 14 days) transfusion during the operation (total hip replacement arthroplasty)
Study NCT03745482 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar Mobilisations
Description: The intervention will consist of unilateral lumbar mobilisations at the L4 and L5 level in a Posterior Anterior direction. The side of the mobilisation will be determined by dominant leg - considered the kicking foot. The mobilisations will be administered by a physiotherapist with at least 10 years clinical experience. Teksan grip sensors will be worn by the physiotherapist to calculate the force applied to the participant. Grade three mobilisations will be applied for a one minute period three times at both L4 and L5 level. Each level will be determined by a passive physiological intervertebral movement. Participants will receive the mobilisations at L5 first for one minute followed by L4. This is an appropriate dose for mobilisation application (Maitland, 2013). This process will be carried out three times.
Study NCT04001985 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No clamp trial
Description: Once the NG tube output is less than 500 mL over a 24 hour period with at least two other signs of return of bowel function the NG tube will be removed. Other signs of bowel function include flatus, bowel movement, change of NG tube output from bilious to more clear/frothy character, and hunger.
Study NCT04001985 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clamp trial
Description: Once the NG tube output is less than 500 mL over a 24 hour period with at least two other signs of return of bowel function, a 4 hour clamp trial will be performed. Other signs of bowel function include flatus, bowel movement, change of NG tube output from bilious to more clear/frothy character, and hunger. The NG tube will be taken off of suction and clamped. The NG tube is then reconnected to suction at the end of the four hour clamp trial and removed if less 125 mL drains or kept in place if greater than 125 mL drains. The same initial criteria are used again to determine if a clamp trial will be performed after 24 hours.
Study NCT02343731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Introduction of a dog into the home
Description: Participants will foster dogs from the HSSA for three months while they are in the study.
Study NCT03968120 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Change of ventilatory settings
Description: Change of Positive End-Exspiratory Pressure during one-lung ventilation
Study NCT03481023 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EnsoETM
Description: Use of esophageal thermal regulation device during radiofrequency ablation.
Study NCT03481023 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Care
Description: Use of luminal esophageal temperature monitoring during radiofrequency ablation procedure.
Study NCT02491632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT02890394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suboccipital inhibition technique
Description: Suboccipital inhibition technique involves the placement of the hands of the physiotherapist under the patient's head so that fingers can feel the spinous processes of the cervical vertebrae. Then fingers slowly leads upward to contact the occipital condyles. At this point the investigator should gently move your fingers down, finding the space between the condyles and the spinous process of the axis. Remember that the atlas has no spinous process. Then, flexing the metacarpophalangeal joints at 90 degrees, slowly raises the skull
Study NCT02491632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete a graded resistance exercise program and a walking regimen
Study NCT02491632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02491632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02491632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01453530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: A single dose of sugammadex 2 mg/kg iv
Study NCT01453530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine/Glycopyrrolate
Description: A single dose of neostigmine 0.04 mg/kg iv plus glycopyrrolate 0.01 mg/kg iv
Study NCT01453530 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03782025 — intervention group
Intervention type: DRUG
Intervention: Phytomenadione
Description: Blood samples will be taken before and after intravenously prescribed phytomenadione is given. Phytomenadione will be given independently of this study.
Study NCT00315900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depakote ER
Description: depakote ER
Study NCT00315900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seroquel
Description: seroquel
Study NCT00790322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBG
Description: Soluble beta-1,3/1,6-glucan is a solution for oral use
Study NCT00790322 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for oral use
Study NCT02284451 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video or Pictorial Brochure
Description: Participants will receive HIV/AIDS and HIV testing information by video or by pictorial brochure according to patient health literacy level (lower or higher) and language (English or Spanish).
Study NCT02957721 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Patients will not be given the intervention but receive usual care for T2D.
Study NCT04345835 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutanous nephrolithotomy (PCNL)
Description: different procedure positioning
Study NCT00666809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: Vardenafil 10 mg BID p.o. for 12 weeks + 4 weeks follow-up
Study NCT00666809 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID p.o. for 12 weeks + 4 weeks follow-up
Study NCT00413296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levetiracetam
Description: Tablets, dosage 500 mg each ( 1-6 tablets/day)for20 wks
Study NCT00413296 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, Tablets, no active ingredient in the tablets, (1-6tablets/day)for 12 wks in the 2nd phase of the study.
Study NCT00413296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetriracetam
Description: Tablets, 500 mg each (1-6 tablets/day) for 8 wks during the open label phase and for 12 wks during the 2nd phase of the study.
Study NCT00688181 — intervention group
Intervention type: DEVICE
Intervention: The Prefyx PPS™ Pre-pubic Sling System
Description: device designed to treat female stress urinary incontinence (SUI).
Study NCT02271477 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided volemic repletion
Description: After echocardiography analysis of Inferior Vena Cava, patient is repleted with a pre-established bolus of fluid (500 ml of crystalloid). After this repletion, patient is analyzed till the exam reach signal of non-responsiveness, previously defined as a reduction of Inferior Vena Cava diameter less than 36% from baseline level during normal breath
Study NCT03178539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diclofenac
Description: non steroidal anti-inflammatory drug
Study NCT03178539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketorolac
Description: non steroidal anti-inflammatory drug